Anne Fagan-Niven, PhD

Professor of Neurology

Washington University in St. Louis (WU)

For the past twelve years Anne has been investigating the mechanism(s) by which the E4 isoform of apolipoprotein E (apoE) is a risk factor for Alzheimer’s disease (AD). Her multidisciplinary approach, utilizing biochemical and cell biological experiments coupled with analysis of in vivo transgenic mouse models of AD, has been instrumental in defining an important role for apoE in the metabolism of amyloid-b (Abeta), the protein that accumulates and forms plaques in the AD brain. Over the past ten years, her interests have expanded into the AD biomarker field, with publications describing CSF and in vivo amyloid imaging measures as candidate biomarkers of preclinical and early stage AD. Anne is a co-investigator on the biomarkers portion of a large, long-standing Program Project through the Washington University ADRC investigating brain and cognitive health during healthy aging and dementia. She is also the Principal Investigator of the biomarkers section of a Program Project (Adult Children Study) designed to identify antecedent biomarkers of AD (i.e., biomarkers to detect AD prior to clinical symptoms), and the Biomarker Core Leader for the ADRC.